Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes

  title={Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes},
  author={Gaurav Malviya and Calogero D’Alessandria and Elena Bonanno and Vladimir Vexler and Roberto Massari and Carlo Trotta and Francesco Scopinaro and Rudi A. Dierckx and Alberto Signore},
  journal={Journal of Nuclear Medicine},
  pages={1683 - 1691}
Visilizumab is an IgG2 humanized monoclonal antibody (mAb) characterized by non-FcγR binding and specific to the CD3 antigen, expressed on more than 95% of circulating resting T-lymphocytes and on activated T-lymphocytes homing in inflamed tissues. We hypothesized that the use of a radiolabeled anti-CD3 antibody might serve as a diagnostic tool for imaging T-cell traffic and lymphocytic infiltration of tissues and organs affected by autoimmune diseases. Here we describe the results of in vitro… 

Figures and Tables from this paper

Development of novel radiolabeled anti-CD 20 antibody fragment for B-lymphocyte imaging in Non-Hodgkin ' s lymphoma patients
  • Biology
  • 2011
A new radiolabeled anti-CD20 Fab fragment is developed and evaluated for molecular imaging of tumour infiltrating CD20 positive B-lymphocytes, which will allow a high resolution Positron Emission Tomography (PET) imaging.
N-(4-18F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes
18F-FB-IL2 is stable, is biologically active, and allows in vivo detection of activated T lymphocytes, and capable of stimulating T cells to an extent similar to native IL2.
Isolation and (111)In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model.
The isolation and ex vivo radiolabeling of murine NK cells for the evaluation of cell trafficking in an orthotopic model of human lung cancer in mice and biodistribution is described, which can be used to determine potential effects of immune-mediated therapeutic agents on NK cell biodist distribution.
In vivo Imaging Technologies to Monitor the Immune System
The modalities and immunologic targets that have thus far been explored are described, with the goal of promoting and guiding the future development and application of novel imaging technologies.
Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
The results of this pilot study demonstrate the safety and feasibility of 99mTc-IL2 imaging and has led to a number of hypotheses to be tested in future studies.
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
A highly significant contribution of EC-derived NAMPT to the severity of inflammatory lung injury in both pre-clinical ARDS models is confirmed and the potential for biologic targeting of the eNAMPT/TLR4 inflammatory pathway is highlighted.
Current imaging strategies in rheumatoid arthritis.
This review will discuss advances in both nuclear medicine and MRI strategies for imaging RA with a particular emphasis on molecular imaging, which may enable a more fundamental understanding of critical pathophysiological processes and the advent of new molecular therapies.
A novel bifunctional chelating agent based on bis(hydroxamamide) for 99mTc labeling of polypeptides
The synthesis and biological evaluation of a novel bifunctional chelating agent (BCA) based on bis(hydroxamamide) for 99mTc labeling of polypeptides and C3(BHam)2―COOH as a new BCA is successfully designed and synthesized.
Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study
Findings indicate that lymphopenia in COVID-19 patients is associated with large bowel inflammation supporting the hypothesis that CD4 + lymphocytes migrate to peripheral lymphoid tissues in the bowel.


99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent
Results demonstrate that 99mTc-rituximab of high radiochemical purity and with preserved binding affinity for the antigen can be prepared by photoreduction and that the method shows good reproducibility.
An experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo suggests the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.
Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis.
Examination of patients with severe, active RA after intravenous injection of a 99Tcm-labelled murine anti-human CD4 MAb showed a higher target-to-background ratio in arthritic knee and elbow joints in comparison to polyclonal human immunoglobulin used for conventional imaging, indicating that that anti-CD4 M Ab allows more specific detection of inflammatory infiltrates rich in CD4-positive cells.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy and pharmacokinetics, safety, and immunosuppressive activity of visilizumab in GVHD.
Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
  • C. D’Alessandria, G. Malviya, A. Signore
  • Biology, Medicine
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2007
Scintigraphy with (99m)Tc-Infliximab shows the presence of little TNFalpha in the affected bowel of patients with active CD, suggesting that the clinical benefit that patients have from InflixIMab therapy is unlikely the consequence of a local a reduction of TNF alpha.
Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies
99mTc-labelled CD4-specific antibodies specifically image actively diseased joints in rheumatoid arthritis.
A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis.
This study demonstrates that 111In-1.2B6 scintigraphy is a sensitive method by which to assess RA activity and that targeting is more intense and specific than using 99Tcm-HIG.
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.
Findings suggest that CD3 antibodies can be engineered to lose their toxicity while retaining their potency as immunosuppressants in the management of transplant patients and in therapy of autoimmune diseases.
Use of a Tc-99m labeled anti-TNF alpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies
Scintigraphy with Tc-99m-Infliximab shows the presence of little TNF alpha in the affected bowel of patients with active CD, suggesting that the clinical benefit that patients have from InNetfliximab therapy is unlikely to be a consequence of a local a reduction of TNFalpha.
Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody
It is found that oral anti-CD3 mAb given at doses of 50 and 250 μg/feeding suppressed the incidence of diabetes in this model of STZ-induced diabetes with the best effects seen at the 50 μg/dose.